Wordt geladen...
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
Cancers of nearly all lineages harbor alterations that deregulate mitogen-activated protein kinase signaling, a crucial signaling pathway for tumor formation and maintenance. Of these, KRAS mutations are the most frequent gain-of-function alterations found in patients with cancer. In particular they...
Bewaard in:
| Gepubliceerd in: | Cancer Treat Rev |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7448574/ https://ncbi.nlm.nih.gov/pubmed/32062493 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2020.101978 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|